Skip to main
ARGX
ARGX logo

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 54%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has demonstrated a positive financial trajectory characterized by breakeven operating profits in Q3 2024 and a substantial increase in global product net sales, which reached $737 million in Q4 2024, marking a 29% quarter-over-quarter and 97% year-over-year growth. The company's commitment to innovation is underscored by its ongoing investment in research and development, which accounted for approximately 30% of revenue, aimed at expanding its pipeline targeting rare autoimmune diseases. Moreover, with strong health data supporting its lead product, Vyvgart, and its recent approvals for additional indications, Argenx is well-positioned for sustained growth in the lucrative biopharmaceutical market.

Bears say

Argenx has experienced a slight decrease in R&D expenses, with a 3.0% year-over-year drop to $297.2 million in 4Q23, which raises concerns about the company's financial commitment to innovation amid competitive pressures. The company faces significant risks, including lower-than-anticipated sales growth for its lead product, Vyvgart, and potential setbacks in ongoing clinical trials, which could negatively impact future revenues. Additionally, market dynamics suggest a looming threat from increased competition, along with macroeconomic factors that could further hinder growth prospects in Argenx's pipeline for treating rare autoimmune diseases.

argenx (ARGX) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 54% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 28 analysts, argenx (ARGX) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $602.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $602.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.